Literature DB >> 1590802

Antagonistic effect of triphenylethylenic antiestrogens on the association of estrogen receptor to calmodulin.

A Bouhoute1, G Leclercq.   

Abstract

Binding of (3H)-estradiol labeled estrogen receptor from uterine cytosol to calmodulin was demonstrated by both affinity chromatography and sucrose gradient sedimentation. Triphenylethylene antiestrogens (tamoxifen family) with strong antagonistic activity against the calmodulin-dependent c-AMP phosphodiesterase largely reduced the binding of the receptor. Relevance of this observation with regard to the major antiproliferative activity (cytotoxicity) of these drugs is discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1590802     DOI: 10.1016/s0006-291x(05)80043-9

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Calmodulin binds HER2 and modulates HER2 signaling.

Authors:  Colin D White; Zhigang Li; David B Sacks
Journal:  Biochim Biophys Acta       Date:  2010-12-24

2.  Calmodulin Lobes Facilitate Dimerization and Activation of Estrogen Receptor-α.

Authors:  Zhigang Li; Yonghong Zhang; Andrew C Hedman; James B Ames; David B Sacks
Journal:  J Biol Chem       Date:  2017-02-07       Impact factor: 5.157

3.  Tamoxifen, 17beta-oestradiol and the calmodulin antagonist J8 inhibit human melanoma cell invasion through fibronectin.

Authors:  L O Dewhurst; J W Gee; I G Rennie; S MacNeil
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 4.  Decoding the Therapeutic Implications of the ERα Stability and Subcellular Distribution in Breast Cancer.

Authors:  Angeles C Tecalco-Cruz; Marina Macías-Silva; Josué Orlando Ramírez-Jarquín; Uri Nimrod Ramírez-Jarquín
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-13       Impact factor: 6.055

5.  Biosensor-based approach identifies four distinct calmodulin-binding domains in the G protein-coupled estrogen receptor 1.

Authors:  Quang-Kim Tran; Mark Vermeer
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.